A Phase 2 Multicenter, Randomized, Open-label, Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma

ID Number 15-1265

Principal Investigator(s)
Philip Friedlander

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to find out more about talimogene laherparepvec when given before surgery in people with advanced melanoma who are eligible for complete surgical removal (excision) of their melanoma.

The study will see if talimogene laherparepvec followed by surgery to remove (excise) a melanoma tumor can decrease the likelihood of recurrence of the tumor (replace or return of the tumor) after the surgery in people with advanced melanoma.  The study will also see if talimogene lahparepvec followed by surgery to remove (excise) the melanoma tumor is safe for people with advanced melanoma to take.

Contact Information
Deborah Lehrer
(212) 824-7309

Recruiting Patients: Yes